Research ExplorerPublicationsA unified classification approach rating clinical utility of...

A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases

Standard

A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. / Bernhardt, Alexander M; Tiedt, Steffen; Teupser, Daniel; Dichgans, Martin; Meyer, Bernhard; Gempt, Jens; Kuhn, Peer-Hendrik; Simons, Mikael; Palleis, Carla; Weidinger, Endy; Nübling, Georg; Holdt, Lesca; Hönikl, Lisa; Gasperi, Christiane; Giesbertz, Pieter; Müller, Stephan A; Breimann, Stephan; Lichtenthaler, Stefan F; Kuster, Bernhard; Mann, Matthias; Imhof, Axel; Barth, Teresa; Hauck, Stefanie M; Zetterberg, Henrik; Otto, Markus; Weichert, Wilko; Hemmer, Bernhard; Levin, Johannes.

In: EBIOMEDICINE, Vol. 89, 03.2023, p. 104456.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Bernhardt, AM, Tiedt, S, Teupser, D, Dichgans, M, Meyer, B, Gempt, J, Kuhn, P-H, Simons, M, Palleis, C, Weidinger, E, Nübling, G, Holdt, L, Hönikl, L, Gasperi, C, Giesbertz, P, Müller, SA, Breimann, S, Lichtenthaler, SF, Kuster, B, Mann, M, Imhof, A, Barth, T, Hauck, SM, Zetterberg, H, Otto, M, Weichert, W, Hemmer, B & Levin, J 2023, 'A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases', EBIOMEDICINE, vol. 89, pp. 104456. https://doi.org/10.1016/j.ebiom.2023.104456

APA

Bernhardt, A. M., Tiedt, S., Teupser, D., Dichgans, M., Meyer, B., Gempt, J., Kuhn, P-H., Simons, M., Palleis, C., Weidinger, E., Nübling, G., Holdt, L., Hönikl, L., Gasperi, C., Giesbertz, P., Müller, S. A., Breimann, S., Lichtenthaler, S. F., Kuster, B., ... Levin, J. (2023). A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. EBIOMEDICINE, 89, 104456. https://doi.org/10.1016/j.ebiom.2023.104456

Vancouver

Bernhardt AM, Tiedt S, Teupser D, Dichgans M, Meyer B, Gempt J et al. A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. EBIOMEDICINE. 2023 Mar;89:104456. https://doi.org/10.1016/j.ebiom.2023.104456

Bibtex

@article{7eb3552dd2d6467b87eed28031b0a986,
title = "A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases",
abstract = "A major evolution from purely clinical diagnoses to biomarker supported clinical diagnosing has been occurring over the past years in neurology. High-throughput methods, such as next-generation sequencing and mass spectrometry-based proteomics along with improved neuroimaging methods, are accelerating this development. This calls for a consensus framework that is broadly applicable and provides a spot-on overview of the clinical validity of novel biomarkers. We propose a harmonized terminology and a uniform concept that stratifies biomarkers according to clinical context of use and evidence levels, adapted from existing frameworks in oncology with a strong focus on (epi)genetic markers and treatment context. We demonstrate that this framework allows for a consistent assessment of clinical validity across disease entities and that sufficient evidence for many clinical applications of protein biomarkers is lacking. Our framework may help to identify promising biomarker candidates and classify their applications by clinical context, aiming for routine clinical use of (protein) biomarkers in neurology.",
keywords = "Humans, Biomarkers, Nervous System Diseases, Proteomics/methods, Mass Spectrometry, Neuroimaging",
author = "Bernhardt, {Alexander M} and Steffen Tiedt and Daniel Teupser and Martin Dichgans and Bernhard Meyer and Jens Gempt and Peer-Hendrik Kuhn and Mikael Simons and Carla Palleis and Endy Weidinger and Georg N{\"u}bling and Lesca Holdt and Lisa H{\"o}nikl and Christiane Gasperi and Pieter Giesbertz and M{\"u}ller, {Stephan A} and Stephan Breimann and Lichtenthaler, {Stefan F} and Bernhard Kuster and Matthias Mann and Axel Imhof and Teresa Barth and Hauck, {Stefanie M} and Henrik Zetterberg and Markus Otto and Wilko Weichert and Bernhard Hemmer and Johannes Levin",
note = "Copyright {\textcopyright} 2023 The Author(s). Published by Elsevier B.V. All rights reserved.",
year = "2023",
month = mar,
doi = "10.1016/j.ebiom.2023.104456",
language = "English",
volume = "89",
pages = "104456",
journal = "EBIOMEDICINE",
issn = "2352-3964",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases

AU - Bernhardt, Alexander M

AU - Tiedt, Steffen

AU - Teupser, Daniel

AU - Dichgans, Martin

AU - Meyer, Bernhard

AU - Gempt, Jens

AU - Kuhn, Peer-Hendrik

AU - Simons, Mikael

AU - Palleis, Carla

AU - Weidinger, Endy

AU - Nübling, Georg

AU - Holdt, Lesca

AU - Hönikl, Lisa

AU - Gasperi, Christiane

AU - Giesbertz, Pieter

AU - Müller, Stephan A

AU - Breimann, Stephan

AU - Lichtenthaler, Stefan F

AU - Kuster, Bernhard

AU - Mann, Matthias

AU - Imhof, Axel

AU - Barth, Teresa

AU - Hauck, Stefanie M

AU - Zetterberg, Henrik

AU - Otto, Markus

AU - Weichert, Wilko

AU - Hemmer, Bernhard

AU - Levin, Johannes

N1 - Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

PY - 2023/3

Y1 - 2023/3

N2 - A major evolution from purely clinical diagnoses to biomarker supported clinical diagnosing has been occurring over the past years in neurology. High-throughput methods, such as next-generation sequencing and mass spectrometry-based proteomics along with improved neuroimaging methods, are accelerating this development. This calls for a consensus framework that is broadly applicable and provides a spot-on overview of the clinical validity of novel biomarkers. We propose a harmonized terminology and a uniform concept that stratifies biomarkers according to clinical context of use and evidence levels, adapted from existing frameworks in oncology with a strong focus on (epi)genetic markers and treatment context. We demonstrate that this framework allows for a consistent assessment of clinical validity across disease entities and that sufficient evidence for many clinical applications of protein biomarkers is lacking. Our framework may help to identify promising biomarker candidates and classify their applications by clinical context, aiming for routine clinical use of (protein) biomarkers in neurology.

AB - A major evolution from purely clinical diagnoses to biomarker supported clinical diagnosing has been occurring over the past years in neurology. High-throughput methods, such as next-generation sequencing and mass spectrometry-based proteomics along with improved neuroimaging methods, are accelerating this development. This calls for a consensus framework that is broadly applicable and provides a spot-on overview of the clinical validity of novel biomarkers. We propose a harmonized terminology and a uniform concept that stratifies biomarkers according to clinical context of use and evidence levels, adapted from existing frameworks in oncology with a strong focus on (epi)genetic markers and treatment context. We demonstrate that this framework allows for a consistent assessment of clinical validity across disease entities and that sufficient evidence for many clinical applications of protein biomarkers is lacking. Our framework may help to identify promising biomarker candidates and classify their applications by clinical context, aiming for routine clinical use of (protein) biomarkers in neurology.

KW - Humans

KW - Biomarkers

KW - Nervous System Diseases

KW - Proteomics/methods

KW - Mass Spectrometry

KW - Neuroimaging

U2 - 10.1016/j.ebiom.2023.104456

DO - 10.1016/j.ebiom.2023.104456

M3 - SCORING: Review article

C2 - 36745974

VL - 89

SP - 104456

JO - EBIOMEDICINE

JF - EBIOMEDICINE

SN - 2352-3964

ER -